Vaccinex, Inc. (VCNX) |
|
0.4879 0.047 (10.53%)
|
11-28 16:00 |
|
Open: |
0.5 |
Pre. Close: |
0.4414 |
|
High:
|
0.53 |
Low:
|
0.447 |
|
Volume:
|
193,542 |
Market Cap:
|
21(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 4:44:00 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.65 One year: 0.75 |
| Support: |
Support1: 0.41 Support2: 0.34 |
| Resistance: |
Resistance1: 0.55 Resistance2: 0.64 |
| Pivot: |
0.53  |
| Moving Average: |
MA(5): 0.46 MA(20): 0.54
MA(100): 0.77 MA(250): 1.07 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 17.4 %D(3): 8.7 |
| RSI: |
RSI(14): 41.7 |
| 52-week: |
High: 2.27 Low: 0.41 |
| Average Vol(K): |
3-Month: 69 (K) 10-Days: 55 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VCNX ] has closed above bottom band by 29.1%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.53 - 0.53 |
0.53 - 0.54 |
|
Low:
|
0.44 - 0.44 |
0.44 - 0.45 |
|
Close:
|
0.48 - 0.49 |
0.49 - 0.49 |
|
Company Description |
|
Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. |
Headline News |
Mon, 28 Nov 2022
Should You Accumulate Vaccinex Inc (VCNX) Stock Monday? - InvestorsObserver
Mon, 28 Nov 2022
Vaccinex raises $3.8M in direct stock offering (NASDAQ:VCNX) - Seeking Alpha
Mon, 14 Nov 2022
Vaccinex Earnings, Revenue Beat in Q3 By Investing.com - Investing.com
Mon, 14 Nov 2022
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update - Yahoo Finance
Mon, 14 Nov 2022
Vaccinex GAAP EPS of -$0.11, revenue of $0.05M (NASDAQ:VCNX) - Seeking Alpha
Thu, 10 Nov 2022
2022-11-10 | NDAQ:VCNX | Press Release | Vaccinex Inc. - Stockhouse
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
43 (M) |
|
% Held by Insiders
|
2.597e+007 (%) |
|
% Held by Institutions
|
12 (%) |
|
Shares Short
|
86 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.01e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-40 |
|
Return on Assets (ttm)
|
610 |
|
Return on Equity (ttm)
|
-106.7 |
|
Qtrly Rev. Growth
|
50000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-99.72 |
|
EBITDA (p.s.)
|
-1.54857e+007 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-20 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
264280 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
